Folate Testing (Serum and RBC) Coverage Criteria
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and limitations for serum and red blood cell (RBC) folate laboratory testing for Blue Cross Blue Shield - Tennessee members, including indications that meet coverage criteria and tests that are not covered.
No material clinical or coverage changes in this revision.
Coverage Criteria for Folate Testing
inv-01: Serum folate — Covered Indication
Measurement of serum folate concentration MEETS COVERAGE CRITERIA when ALL of the following are met:
Based on policy Section III criteria
inv-02: RBC folate — Not covered
Measurement of red blood cell (RBC) folate
Per policy Section III
inv-03: Serum folate — Not covered indications
Other indications
Per policy Section III
inv-04: When RBC folate or serum folate testing is appropriate
Covered when ANY of the following guideline-supported indications apply:
Do not flatten nested decision logic; these are alternative appropriate indications per specialty guidance.
inv-05: When testing is discouraged
Not generally covered/appropriate when the following applies:
ASCP Choosing Wisely: 'Do not order red blood cell folate levels at all'
inv-06: Algorithm-based testing in macrocytic anemia
Covered when ALL of the following are met per AAFP algorithm:
Directly from AAFP algorithm description in policy.
Per policy Section III, measurement of red blood cell (RBC) folate DOES NOT MEET COVERAGE CRITERIA for any indications. The policy also states that routine serum folate testing does not meet coverage criteria except for the single covered scenario (evaluation of persistent megaloblastic or macrocytic anemia after folic acid treatment). These exclusions reflect guidance that routine ordering of RBC folate or serum folate in folic acid–fortified populations rarely influences management and therefore is not supported.
The policy cites ASCP/Choosing Wisely guidance that explicitly recommends ‘Do not order red blood cell folate levels at all’ and advises that in adults with macrocytic anemia clinicians should consider folate supplementation instead of routine serum folate testing. As implemented in this policy, routine RBC folate testing in adults where the result will not change management is discouraged and generally not covered.
The policy references advisory statements (ASCP Choosing Wisely and other cited sources) that recommend against routine RBC folate testing because results seldom alter diagnosis or treatment. The ASCP guidance summarized in the policy states that historical uses of RBC folate as a surrogate for tissue stores do not generally add to clinical decision-making in adults in the current fortified-food context.
Evidence cited in the policy documents (Shojania & von Kuster; Joelson et al.; others) concludes that routine folate measurements (serum or RBC) are of low utility in folic acid–fortified countries due to a markedly reduced incidence of folate-deficiency anemia after fortification. These studies report very low yields for folate deficiency among tested patients and question the value of routine testing.
ASCP/Choosing Wisely is cited in the policy as advising clinicians not to order RBC folate routinely and to favor empiric folic acid supplementation in many adult cases of macrocytic anemia. The policy uses this advisory statement to justify the lack of coverage for RBC folate testing in virtually all routine adult scenarios.
Indications Covered by Policy
inv-36: Evaluation of patients with megaloblastic or macrocytic anemia that persists after folic acid treatment
Serum folate testing covered only in this scenario:
Serum folate testing meets coverage criteria only for this indication
inv-37: Evaluation of suspected folate deficiency in selected high-risk or symptomatic patients (e.g., unexplained macrocytic/megaloblastic anemia, post-bariatric surgery, malabsorptive conditions, IBD with risk factors).
Testing appropriate for selected high‑risk or symptomatic patients when ANY apply:
Supported by AACE/ASMBS/ASMBS-related perioperative guidelines, ECCO, and BCSH guidance; some societies prefer RBC folate when serum equivocal.
inv-38: Initial evaluation for myelodysplastic syndromes (NCCN recommends RBC folate as part of initial evaluation).
Per specialty guidance:
NCCN recommendation
inv-39: Investigation of suspected folate deficiency in specific clinical contexts (e.g., macrocytic anemia, malabsorption, per cited clinical guidelines).
Investigation of suspected folate deficiency in the following specific clinical contexts (per cited guidelines):
Cited guideline sources include BCMA, BCSH, UpToDate and perioperative bariatric guidelines
Tests and Indications Not Covered
The policy explicitly lists as NOT COVERED: red blood cell (RBC) folate testing for any indication. It further specifies that serum folate testing is not covered except when used to evaluate patients with megaloblastic or macrocytic anemia that persists after folic acid treatment (the single covered indication described in Section III).
Ordering RBC folate testing as a routine test in adults without specific guideline-supported indications is discouraged by ASCP/Choosing Wisely and, per the policy, may be considered not covered. The policy therefore treats routine RBC folate in adults where results will not change management as a non-covered service.
The policy notes that routine or reflex ordering of RBC or serum folate assays in countries with folic acid fortification is questioned or discouraged by cited guidance and empirical studies showing very low prevalence of folate-deficiency anemia after fortification. Consequently, routine or reflex testing in a fortified population is discouraged and not supported as medically necessary.
Provider Actions, Documentation, and Prior Authorization
Prior Authorization Required / Coverage Criteria
Measurement of serum folate concentration meets coverage criteria only when BOTH of the following are present: a diagnosis of megaloblastic or macrocytic anemia; and megaloblastic anemia and/or macrocytosis that does not resolve after folic acid treatment. Measurement of serum folate does not meet coverage criteria for any other indications. Measurement of red blood cell (RBC) folate does not meet coverage criteria for any indications except in limited conditional circumstances described below.
- Covered indication: Evaluation of megaloblastic/macrocytic anemia when anemia does not resolve after folic acid treatment.
- Not covered: Serum folate for indications other than above; RBC folate generally not covered.
RBC Folate Testing Discouraged
The ASCP/Choosing Wisely recommendation discourages ordering RBC folate levels in adults and suggests considering folate supplementation instead of routine serum folate testing in patients with macrocytic anemia. Local payer coverage follows this guidance by generally not covering RBC folate testing.
- Do not order RBC folate levels routinely; consider empiric folic acid supplementation in adults with macrocytic anemia.
- RBC folate testing is discouraged and generally not covered.
Documentation Required for RBC Folate (Conditional)
When evaluating macrocytic anemia, RBC folate measurement may be considered only under specific conditional documentation: patient with MCV ≥100 fL, abnormal peripheral smear showing megaloblastic features, reticulocyte count <2%, and after ruling out or documenting vitamin B12 status (e.g., measure RBC folate only if B12 level >400 pg in the referenced algorithm). Documentation must support the diagnosis and prior folic acid treatment and why serum testing alone is insufficient.
- RBC folate may be measured only when: MCV ≥100 fL; abnormal peripheral smear with megaloblastic features; reticulocyte count <2%; and vitamin B12 assessment completed (e.g., B12 >400 pg as a conditional trigger in referenced algorithm).
- Required documentation: clinical evidence supporting megaloblastic/macrocytic anemia, peripheral smear findings, reticulocyte count, B12 results, and record of folic acid treatment and lack of resolution.
Step Therapy / Alternative
Guidance and step-therapy: consider empiric folic acid supplementation in adults with macrocytic anemia instead of routine folate testing. Folate and vitamin B12 should generally be tested together when evaluating deficiency.
- Consider empiric folic acid supplementation in adults with macrocytic anemia rather than routine serum or RBC folate testing.
- When testing, order serum folate and vitamin B12 together; in some scenarios supplementation without testing is acceptable (e.g., pregnancy and certain hemolytic conditions per BCSH recommendations).
Listed Procedure Codes / Billing Reminder
Procedure codes listed below are provided for billing and prior authorization reference only and may not be all-inclusive. Include appropriate clinical documentation with any prior authorization or claim submission.
Procedure Codes and Coding Details
Provider action: consider supplementation before ordering tests
When ordering for adults with macrocytic anemia, clinicians should consider empiric folic acid supplementation as an alternative to immediate folate testing in line with Choosing Wisely recommendations.
Recommended Monitoring Frequency
Ordering Considerations and Clinician Guidance
Ordering consideration: empiric supplementation for macrocytic anemia
Consider empiric folic acid supplementation instead of ordering folate testing in adults with macrocytic anemia; this is an explicit ordering consideration in the policy.
Ordering consideration: assess patient-specific risk factors
Clinicians should account for patient‑specific risk factors (for example, pre‑operative bariatric assessment, pregnancy planning, or symptomatic anemia) and follow guideline recommendations about when laboratory folate testing is appropriate.
- Pre-operative bariatric patients
- Pregnancy planning or pregnancy
- Symptomatic or unexplained anemia
Ordering note: guideline-driven indications, no clinician-type restriction
The policy cites specialty guidelines and advisory statements to define appropriate indications; it does not restrict ordering to specific clinician types in the cited sections.
Background on Folate and Testing
Folate (vitamin B9) is essential for one-carbon transfers required for nucleotide synthesis and for methionine/homocysteine metabolism. Deficiency can produce megaloblastic/macrocytic anemia and is associated with increased risk of neural tube defects; routine food folic acid fortification since 1998 has markedly reduced the prevalence of folate deficiency in the U.S. and Canada.
Definitions and Test Descriptions
Evidence Citations and Guideline Sources
The policy cites multiple guideline and advisory sources to support its coverage stance, including ASCP/Choosing Wisely, BCSH, NCCN, and other specialty society guidance. These references underpin recommendations on when testing is appropriate, when RBC folate may be considered, and advisory statements discouraging routine testing in fortified populations.
Guideline sources cited in the policy that address diagnosis and management of folate deficiency include the American Academy of Family Physicians (AAFP) macrocytic anemia algorithm, the British Committee for Standards in Haematology (BCSH) guidance on folate and B12 deficiencies, NICE guidance on monitoring in selected conditions, and NCCN recommendations for initial evaluation in myelodysplastic syndromes. These guideline references inform the limited, condition-specific situations in which folate testing may be appropriate.
Policy Revision History
Policy adopted (effective) based on Avalon policy recommendation; establishes coverage stance and criteria for serum and RBC folate testing.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.